Triple
T1151211
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
E23680
|
entity |
| Predicate | notableWork |
P4
|
FINISHED |
| Object |
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
|
E131972
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals | Statement: [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, notableWork, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals Context triple: [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, notableWork, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals]
-
A.
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics is a peer-reviewed scientific journal focusing on the discovery, development, and clinical evaluation of novel cancer therapeutics.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
Cancer Res
Cancer Res is a leading peer-reviewed scientific journal that publishes research on the molecular and cellular biology, genetics, and treatment of cancer.
-
D.
NCI-Designated Cancer Centers Program
The NCI-Designated Cancer Centers Program is a U.S. network of leading academic and research institutions recognized for excellence in cancer research, treatment, and prevention.
-
E.
National Institutes of Health intramural research program
The National Institutes of Health intramural research program is a large, government-funded biomedical research enterprise in which NIH scientists conduct basic, translational, and clinical studies within NIH facilities.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals Triple: [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, notableWork, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals]
Generated description
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals Target entity description: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
A.
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics is a peer-reviewed scientific journal focusing on the discovery, development, and clinical evaluation of novel cancer therapeutics.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
Cancer Res
Cancer Res is a leading peer-reviewed scientific journal that publishes research on the molecular and cellular biology, genetics, and treatment of cancer.
-
D.
NCI-Designated Cancer Centers Program
The NCI-Designated Cancer Centers Program is a U.S. network of leading academic and research institutions recognized for excellence in cancer research, treatment, and prevention.
-
E.
National Institutes of Health intramural research program
The National Institutes of Health intramural research program is a large, government-funded biomedical research enterprise in which NIH scientists conduct basic, translational, and clinical studies within NIH facilities.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a493f0d32c8190ac74bad3c87f2641 |
completed | March 1, 2026, 7:30 p.m. |
| NER | Named-entity recognition | batch_69a4bc744e7c81908f8612f2aad28600 |
completed | March 1, 2026, 10:23 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac5eb5d36c8190916a43a5f41df144 |
completed | March 7, 2026, 5:21 p.m. |
| NEDg | Description generation | batch_69ac5f4756b08190b3dbaf64a9351836 |
completed | March 7, 2026, 5:24 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ac600f78148190bd3109276f7b9e3a |
completed | March 7, 2026, 5:27 p.m. |
Created at: March 1, 2026, 7:44 p.m.